These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Development of Heptylmannoside-Based Glycoconjugate Antiadhesive Compounds against Adherent-Invasive Escherichia coli Bacteria Associated with Crohn's Disease. Sivignon A; Yan X; Alvarez Dorta D; Bonnet R; Bouckaert J; Fleury E; Bernard J; Gouin SG; Darfeuille-Michaud A; Barnich N mBio; 2015 Nov; 6(6):e01298-15. PubMed ID: 26578673 [TBL] [Abstract][Full Text] [Related]
3. Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin. Bouckaert J; Berglund J; Schembri M; De Genst E; Cools L; Wuhrer M; Hung CS; Pinkner J; Slättegård R; Zavialov A; Choudhury D; Langermann S; Hultgren SJ; Wyns L; Klemm P; Oscarson S; Knight SD; De Greve H Mol Microbiol; 2005 Jan; 55(2):441-55. PubMed ID: 15659162 [TBL] [Abstract][Full Text] [Related]
4. The Antiadhesive Strategy in Crohn's Disease: Orally Active Mannosides to Decolonize Pathogenic Escherichia coli from the Gut. Alvarez Dorta D; Sivignon A; Chalopin T; Dumych TI; Roos G; Bilyy RO; Deniaud D; Krammer EM; de Ruyck J; Lensink MF; Bouckaert J; Barnich N; Gouin SG Chembiochem; 2016 May; 17(10):936-52. PubMed ID: 26946458 [TBL] [Abstract][Full Text] [Related]
5. Development of an aggregation assay to screen FimH antagonists. Abgottspon D; Rölli G; Hosch L; Steinhuber A; Jiang X; Schwardt O; Cutting B; Smiesko M; Jenal U; Ernst B; Trampuz A J Microbiol Methods; 2010 Sep; 82(3):249-55. PubMed ID: 20620174 [TBL] [Abstract][Full Text] [Related]
6. In Vivo Consumption of Cranberry Exerts ex Vivo Antiadhesive Activity against FimH-Dominated Uropathogenic Escherichia coli: A Combined in Vivo, ex Vivo, and in Vitro Study of an Extract from Vaccinium macrocarpon. Rafsanjany N; Senker J; Brandt S; Dobrindt U; Hensel A J Agric Food Chem; 2015 Oct; 63(40):8804-18. PubMed ID: 26330108 [TBL] [Abstract][Full Text] [Related]
7. Rational design strategies for FimH antagonists: new drugs on the horizon for urinary tract infection and Crohn's disease. Mydock-McGrane LK; Hannan TJ; Janetka JW Expert Opin Drug Discov; 2017 Jul; 12(7):711-731. PubMed ID: 28506090 [TBL] [Abstract][Full Text] [Related]
12. Development of Mannopyranoside Therapeutics against Adherent-Invasive Escherichia coli Infections. Mousavifar L; Touaibia M; Roy R Acc Chem Res; 2018 Nov; 51(11):2937-2948. PubMed ID: 30289687 [TBL] [Abstract][Full Text] [Related]
13. Antivirulence Isoquinolone Mannosides: Optimization of the Biaryl Aglycone for FimH Lectin Binding Affinity and Efficacy in the Treatment of Chronic UTI. Jarvis C; Han Z; Kalas V; Klein R; Pinkner JS; Ford B; Binkley J; Cusumano CK; Cusumano Z; Mydock-McGrane L; Hultgren SJ; Janetka JW ChemMedChem; 2016 Feb; 11(4):367-73. PubMed ID: 26812660 [TBL] [Abstract][Full Text] [Related]
14. Glycan-functionalized diamond nanoparticles as potent E. coli anti-adhesives. Barras A; Martin FA; Bande O; Baumann JS; Ghigo JM; Boukherroub R; Beloin C; Siriwardena A; Szunerits S Nanoscale; 2013 Mar; 5(6):2307-16. PubMed ID: 23396565 [TBL] [Abstract][Full Text] [Related]
15. Biofilm formation by multidrug resistant Escherichia coli ST131 is dependent on type 1 fimbriae and assay conditions. Sarkar S; Vagenas D; Schembri MA; Totsika M Pathog Dis; 2016 Apr; 74(3):. PubMed ID: 26940589 [TBL] [Abstract][Full Text] [Related]
16. A flow cytometry-based assay for screening FimH antagonists. Scharenberg M; Abgottspon D; Cicek E; Jiang X; Schwardt O; Rabbani S; Ernst B Assay Drug Dev Technol; 2011 Oct; 9(5):455-64. PubMed ID: 21675870 [TBL] [Abstract][Full Text] [Related]
17. Second generation of thiazolylmannosides, FimH antagonists for E. coli-induced Crohn's disease. Chalopin T; Alvarez Dorta D; Sivignon A; Caudan M; Dumych TI; Bilyy RO; Deniaud D; Barnich N; Bouckaert J; Gouin SG Org Biomol Chem; 2016 Apr; 14(16):3913-25. PubMed ID: 27043998 [TBL] [Abstract][Full Text] [Related]
19. The affinity of the FimH fimbrial adhesin is receptor-driven and quasi-independent of Escherichia coli pathotypes. Bouckaert J; Mackenzie J; de Paz JL; Chipwaza B; Choudhury D; Zavialov A; Mannerstedt K; Anderson J; Piérard D; Wyns L; Seeberger PH; Oscarson S; De Greve H; Knight SD Mol Microbiol; 2006 Sep; 61(6):1556-68. PubMed ID: 16930149 [TBL] [Abstract][Full Text] [Related]
20. The potential of FimH as a novel therapeutic target for the treatment of Crohn's disease. Sivignon A; Bouckaert J; Bernard J; Gouin SG; Barnich N Expert Opin Ther Targets; 2017 Sep; 21(9):837-847. PubMed ID: 28762293 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]